List of Excipients in Branded Drug GLUCAGON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fresenius Kabi USA LLC	GLUCAGON	glucagon	63323-596	HYDROCHLORIC ACID
Fresenius Kabi USA LLC	GLUCAGON	glucagon	63323-596	LACTOSE MONOHYDRATE
Fresenius Kabi USA LLC	GLUCAGON	glucagon	63323-596	SODIUM HYDROXIDE

Glucagon Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Glucagon is shifting from a hospital-rescue injectable to a consumer-administered emergency product. The commercial opportunity is concentrated in four areas: ready-to-use liquid formulations, needle-free nasal delivery, pediatric and mini-dose rescue, and next-generation glucagon analogs for automated insulin systems. Excipient selection determines stability, device compatibility, usability, and regulatory differentiation.

The main marketed U.S. products use distinct formulation strategies:

Product	Active ingredient	Route and presentation	Principal excipient strategy	Commercial positioning
GlucaGen HypoKit	Recombinant human glucagon	Lyophilized powder plus diluent	Lactose-based cake; reconstitution before use	Established emergency injection
Generic glucagon for injection	Recombinant human glucagon	Lyophilized powder plus diluent	Similar lactose-based formulation	Low-cost hospital and retail substitute
Gvoke HypoPen and prefilled syringe	Dasiglucagon	Ready-to-use subcutaneous liquid	Glycerol and m-cresol in acidic aqueous solution	Needle-based, room-temperature rescue
Zegalogue	Dasiglucagon	Ready-to-use autoinjector and prefilled syringe	Glycerol and phenolic preservative system in aqueous solution	Human-factor and stability differentiation
Baqsimi	Recombinant human glucagon	Dry intranasal powder	Betadex and dodecylphosphocholine	Needle-free emergency rescue

The strongest near-term commercial position is held by products that eliminate reconstitution and reduce administration errors. The strongest longer-term opportunity is a stable glucagon formulation compatible with automated pumps, wearable devices, or dual-hormone systems.

What excipients are used in marketed glucagon products?

How does the traditional glucagon injection formulation work?

Traditional glucagon injection is supplied as a sterile lyophilized cake. The active ingredient is recombinant glucagon hydrochloride, generally packaged with lactose as a bulking and stabilizing excipient. The user adds sterile water immediately before administration. The solution is then injected subcutaneously, intramuscularly, or intravenously depending on the product and indication. [1]

This architecture addresses glucagon’s limited stability in aqueous solution but creates several commercial disadvantages:

• Reconstitution takes multiple steps.
• The emergency user must handle a vial, syringe, and diluent.
• Dose preparation creates opportunities for delay or error.
• The reconstituted product has limited in-use stability.
• Device integration is difficult.

Lactose is commercially familiar and compatible with lyophilization. Its disadvantages include the need for a dry-powder manufacturing process and dependence on a separate diluent. The formulation is suitable for hospital emergency kits but less attractive for unsupervised home use.

What excipients are used in ready-to-use dasiglucagon products?

Gvoke and Zegalogue use dasiglucagon, a glucagon analog designed for aqueous formulation. Their labels identify glycerol and a phenolic preservative system among the inactive ingredients, with pH adjustment using hydrochloric acid or sodium hydroxide. [2,3]

The formulation strategy has three objectives:

1. Maintain glucagon analog stability in a ready-to-use liquid.
2. Support storage in a prefilled syringe or autoinjector.
3. Eliminate user reconstitution.

Glycerol can contribute to tonicity and protein stabilization. A phenolic preservative can control microbial growth in multidose or device presentations, although the concentration and container-contact profile must be controlled carefully. The acidic formulation must also be assessed for extractables, leachables, metal compatibility, silicone-oil interactions, and injection-site tolerability.

Dasiglucagon has an important formulation advantage over native glucagon: it was engineered to remain soluble and stable in aqueous conditions. That creates a broader device and presentation opportunity than traditional lyophilized glucagon.

What excipients are used in Baqsimi nasal glucagon?

Baqsimi is a 3 mg intranasal dry-powder product. Its formulation uses betadex, a cyclodextrin derivative, and dodecylphosphocholine as principal inactive ingredients. The powder is delivered through a single-use nasal device without reconstitution or injection. [4]

The excipient system must support:

• Powder dispersibility.
• Nasal mucosal deposition.
• Rapid dissolution in low fluid volume.
• Chemical stability during storage.
• Consistent emitted dose.
• Tolerance of nasal irritation and congestion.
• Robustness against device humidity exposure.

The nasal route expands the addressable market beyond patients and caregivers comfortable with needles. It also creates intellectual-property opportunities around powder engineering, device geometry, moisture protection, dose metering, and nasal absorption enhancers.

What formulation patents protect glucagon products?

Patent protection for glucagon products typically falls into five categories:

Patent category	Protected subject matter	Commercial relevance
Composition patents	Glucagon analog sequence, salts, purity, or stabilized composition	Can block substitution with chemically distinct analogs
Formulation patents	pH, buffer, stabilizer, preservative, surfactant, and concentration ranges	Can constrain ready-to-use liquid competition
Device patents	Autoinjectors, prefilled syringes, nasal dispensers, and safety mechanisms	Can delay device-equivalent launches
Method-of-use patents	Emergency treatment, severe hypoglycemia, pediatric use, or pump-related dosing	Can support branded indications
Manufacturing patents	Recombinant production, purification, crystallization, drying, or filling	Can increase development and scale-up barriers

GlucaGen and generic glucagon products depend mainly on established recombinant-glucagon and lyophilized-injection technology. Gvoke and Zegalogue have stronger formulation differentiation because their commercial value depends on a stable liquid presentation of dasiglucagon. Baqsimi’s protection is more dependent on the nasal powder and delivery system than on the underlying glucagon molecule.

What is the Orange Book status of glucagon products?

FDA Orange Book listings should be reviewed product by product because listed patents, pediatric exclusivity, and regulatory exclusivity can change. Injectable biologic or peptide products may not have the same Orange Book profile as conventional small-molecule tablets, and a listed patent is not equivalent to a complete prohibition on development.

For commercial diligence, the relevant questions are:

• Whether the product is approved under a drug or biologic pathway.
• Whether patents are listed in the Orange Book.
• Whether a competitor can file an abbreviated application.
• Whether a 505(b)(2) pathway is available for a new route, formulation, or device.
• Whether the proposed product requires a full application because it uses a new glucagon analog.
• Whether a device constituent creates separate freedom-to-operate risks.

When does glucagon lose exclusivity?

Native recombinant glucagon is already exposed to generic competition in the conventional vial-and-diluent format. The principal remaining exclusivity value lies in product-specific formulations, devices, analog sequences, and approved uses.

Dasiglucagon products are more vulnerable to formulation and device-based competition than to direct substitution with conventional glucagon. A competitor could pursue:

• A ready-to-use native glucagon formulation.
• A different glucagon analog.
• A nasal powder with a different absorption-enhancing system.
• A prefilled syringe rather than an autoinjector.
• A 505(b)(2) product relying on established glucagon safety information.

Exact loss-of-exclusivity analysis requires review of current FDA listings, issued patents, terminal disclaimers, patent-term adjustments, pediatric extensions, and litigation outcomes. Patent expiration cannot be inferred reliably from approval dates alone.

How strong is the patent estate for glucagon products?

Traditional glucagon injection

The traditional formulation has relatively weak differentiation because lactose-based lyophilized glucagon is established technology and generic versions are available. Defensibility depends on manufacturing scale, supply reliability, packaging, and distribution rather than a unique excipient platform.

Ready-to-use dasiglucagon

The dasiglucagon estate is stronger where claims cover:

• The analog sequence.
• A stable aqueous formulation.
• Defined pH and excipient concentrations.
• Long-term storage conditions.
• Prefilled delivery systems.
• Autoinjector operation.
• Emergency-use instructions.

The commercial risk is that a competitor may design around a formulation claim by changing the analog, preservative, concentration, pH, container, or device. Broad composition claims are more valuable than narrow claims limited to a single excipient range.

Nasal glucagon

Baqsimi has a differentiated route and delivery platform. Its competitive barriers include powder manufacture, nasal deposition, dose uniformity, device performance, and clinical bridging. The patent estate may be technically narrower than a broad injectable analog estate, but the development burden for a clinically equivalent nasal product is substantial.

What commercial opportunities exist for glucagon excipients?

Which excipients offer the clearest opportunity?

The most attractive excipient opportunities are not commodity substitution alone. They involve enabling a superior presentation or reducing manufacturing risk.

Stabilizers for ready-to-use aqueous glucagon

Potential development areas include:

• Polyols such as glycerol or sorbitol.
• Amino-acid stabilizers.
• Low-level nonionic surfactants.
• Alternative preservatives.
• Buffer systems that reduce aggregation and adsorption.
• Container-compatible protein-stabilizing systems.

A successful formulation must preserve potency without increasing injection pain, aggregation, particulate formation, or device compatibility problems.

Preservative alternatives

Phenolic preservatives are effective but may create tolerability and container-interaction concerns. A preservative-free single-dose presentation could support premium positioning and simplify pediatric or chronic-device use. The tradeoff is higher manufacturing cost and stricter control of sterility assurance.

Nasal powder carriers

Cyclodextrins, phospholipids, amino acids, and engineered sugars can be evaluated for powder flow, moisture protection, dissolution, and nasal absorption. The commercial opportunity is strongest where an excipient improves dose consistency without requiring a new device.

Lyophilization aids

For conventional glucagon and new analogs, excipients that improve cake structure, reconstitution speed, and post-reconstitution stability can support hospital and emergency-kit products. Mannitol, sucrose, trehalose, and amino-acid systems are possible development categories, but each requires compatibility testing with glucagon and the chosen container closure system.

How do glucagon products compare commercially?

Attribute	Traditional injection	Ready-to-use liquid	Nasal powder
Reconstitution required	Yes	No	No
Needle required	Yes	Usually yes	No
Formulation complexity	Moderate	High	High
Device dependence	Low to moderate	High	High
Home-use suitability	Lower	High	High
Generic substitution risk	High	Moderate	Moderate
Excipient differentiation	Moderate	High	High
Manufacturing barrier	Moderate	High	High
Hospital familiarity	High	Growing	Growing

The traditional product remains important where price and formulary familiarity dominate. Ready-to-use liquid products have the strongest opportunity in emergency kits, schools, pharmacies, ambulances, and households. Nasal glucagon has the clearest user-experience differentiation and avoids needle anxiety.

What generic entry risks exist for glucagon?

Which companies are challenging branded glucagon products?

Generic competition is already established for conventional glucagon injection. The competitive field for ready-to-use and nasal products is less mature because a follow-on entrant must address formulation stability, device performance, clinical usability, and regulatory comparability.

Potential entry routes include:

• Abbreviated applications for products with sufficiently comparable active ingredients and presentations.
• 505(b)(2) applications for new formulations or routes.
• Full applications for new glucagon analogs.
• Device-led products that use a distinct delivery system.
• Authorized generics or contract-manufactured alternatives.

The principal barrier is not the cost of glucagon itself. It is the combination of peptide stability, human factors, container closure, device reliability, and emergency-use performance.

What FDA regulatory issues affect glucagon excipient strategy?

FDA review will focus on:

• Excipient safety by route and dose.
• Stability of the peptide in the proposed presentation.
• Aggregation, degradation, and particulate control.
• Extractables and leachables.
• Delivered-dose uniformity.
• Device reliability under temperature and handling stress.
• Preservative effectiveness where applicable.
• Nasal tolerability for intranasal products.
• Human-factors validation for emergency administration.
• Pediatric acceptability and dosing.

Excipient changes can trigger substantial regulatory work even when the active ingredient is unchanged. A new preservative, nasal absorption enhancer, or liquid stabilizer can alter safety, pharmacokinetics, device performance, and the required clinical package.

What licensing and partnership opportunities exist?

The most actionable partnership targets are:

1. Excipient suppliers with peptide-stabilization platforms.
2. Device companies with autoinjector or nasal-dispensing technology.
3. Contract manufacturers experienced in sterile peptide filling.
4. Diabetes technology companies developing bihormonal pumps.
5. Specialty-pharmacy and emergency-care distributors.
6. Companies with pediatric or school-based diabetes channels.

Licensing value is highest when the technology solves a specific failure point: room-temperature stability, rapid nasal absorption, low-volume delivery, preservative elimination, or integration into a wearable pump.

What is the outlook for glucagon in automated insulin delivery?

Glucagon is a critical component of bihormonal artificial-pancreas systems intended to reduce insulin-induced hypoglycemia. The principal formulation requirement is continuous or repeated delivery in a compact reservoir, often at low dose and under changing temperature conditions.

Traditional glucagon is poorly suited to this use because aqueous stability is limited. A stable glucagon analog or liquid formulation could support:

• Dual-hormone pumps.
• Automated rescue dosing.
• Mini-dose glucagon for exercise.
• Pediatric hypoglycemia prevention.
• Closed-loop systems with predictive low-glucose suspension.
• Wearable emergency delivery.

This market has greater technical and regulatory requirements than rescue products but may produce stronger switching costs and longer-term platform value.

What patent litigation and settlement risks affect glucagon?

Litigation risk is concentrated in three areas:

• Patent infringement claims involving glucagon analog sequences.
• Formulation claims covering ready-to-use liquids.
• Device claims involving autoinjectors, prefilled syringes, and nasal dispensers.

Paragraph IV litigation is more likely for a product seeking approval before expiration of listed patents covering a branded ready-to-use formulation or device. Settlement terms may include delayed entry, licensed manufacture, authorized-generic arrangements, or restrictions on specific presentations. Public litigation and FDA listing databases should be reviewed before relying on any launch date.

Key Takeaways

• Glucagon excipient strategy is moving from lyophilized lactose-based injection toward stable liquid and nasal powder systems.
• Ready-to-use liquid glucagon has the clearest opportunity to replace conventional emergency kits.
• Dasiglucagon products gain commercial value from aqueous stability, device compatibility, and reduced administration complexity.
• Baqsimi’s differentiation comes from nasal delivery, powder engineering, and device performance.
• Generic risk is high for conventional glucagon injection and lower, but increasing, for liquid and nasal products.
• The largest long-term opportunity is stable glucagon for bihormonal pumps and automated hypoglycemia prevention.
• Key IP assets include analog sequences, formulation ranges, device mechanisms, nasal powder systems, and manufacturing processes.
• Excipients can create meaningful commercial differentiation when they improve stability, eliminate reconstitution, enable a new route, or reduce device failure.

FAQs

Can glucagon be formulated without lactose?

Yes. Ready-to-use dasiglucagon products use aqueous excipient systems rather than the traditional lactose-containing lyophilized cake. A lactose-free formulation may improve positioning for specific patient populations, but the primary commercial benefit is elimination of reconstitution.

Why is glucagon difficult to formulate as a liquid?

Glucagon can aggregate, degrade, adsorb to surfaces, and lose potency in aqueous conditions. The formulation must control pH, ionic strength, stabilizer concentration, preservative effects, container interactions, and temperature exposure.

Is nasal glucagon a biologic or a generic drug product?

Regulatory classification depends on the active ingredient, application pathway, and product sponsor. Nasal delivery does not by itself determine whether a product follows an abbreviated or full application route.

What excipient is most important for intranasal glucagon?

No single excipient determines performance. The carrier system must balance powder flow, moisture protection, dissolution, nasal residence, absorption, tolerability, and delivered-dose consistency.

Could a new glucagon excipient create patent protection?

Yes. A patent may protect a specific stabilizer system, concentration range, pH, preservative combination, powder carrier, or device-compatible formulation if the claims satisfy patentability requirements and distinguish over the prior art.

References

1. U.S. Food and Drug Administration. (2023). GlucaGen (glucagon hydrochloride) prescribing information. Novo Nordisk A/S.

2. U.S. Food and Drug Administration. (2023). Gvoke (glucagon injection) prescribing information. Xeris Pharmaceuticals, Inc.

3. U.S. Food and Drug Administration. (2023). Zegalogue (dasiglucagon injection) prescribing information. Zealand Pharma A/S.

4. U.S. Food and Drug Administration. (2023). Baqsimi (glucagon nasal powder) prescribing information. Eli Lilly and Company.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.